The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

HIV Life Cycle

Assembly of Virus

Assembly of infectious virions is dependent on the action of: (a) an aspartyl protease encoded by the viral pol gene and responsible for cleavage of the gag and gag-pol precursors into mature proteins (1,2) and (b) cellular N-protein myristoyl transferase (NMT) which adds myristic acid to the N-terminus of gag, gag-pol and nef viral polyprotein precursors(3). Research on the viral protease was facilitated by previous research on other aspartic proteases, including renin, inhibitors of which have potential as antihypertensive agents. As a result of cloning and purification of the HIV protease, development of rapid enzyme assays (4-10), and elucidation of enzyme structure, potent peptide-based inhibitors of HIV replication and selective for the HIV protease have been developed (11-17).

Potential problems with the use of peptide-based drugs include degradation by proteolytic enzymes and rapid elimination by the liver leading to a short duration of action, and poor bioavailability when taken orally. Chemical modifications to improve these properties is usually necessary.

A group at Abbott Laboratories initially exploited the C2 symmetry of the protease target to design a novel inhibitor with C2 symmetry (17,18). The lead compound was somewhat less peptide-like, containing two peptide N-termini but no C-terminus, and possessed activity against HIV in cell culture comparable to that observed with peptide analogs.

Specific inhibition of the myristoylation of HIV proteins by myristate analogs has also been pursued. Heteroatom substituted analogs of myristate were reported to inhibit HIV-1 replication in acutely infected CD4+ H9 cells at concentrations that were not toxic to uninfected cultured cells (19). Blockade of myristoylation was associated with a dramatic reduction in the rate of proteolytic processing of the polyprotein precursor by viral protease, probably resulting from an inability of the gag and gag-pol precursor to associate with the plasma membrane.



  1. KOHL, N.R.; EMINI, E.A.; SCHLEIF, W.A.; ET AL. Active human immunodeficiency virus protease is required for viral infectivity. PROC NATL ACAD SCI USA, 85:4686-4690 (1988).
  2. PENG, C.; HO, B.K., CHANG, T.W.; CHANG, N.T. Role of human immunodeficiency virus Type 1-specific protease in core protein maturation and viral infectivity. J VIROL 63:2550 (1989).
  3. GOTTLINGER, H.G.; SODROSKI, J.G.; HASELTINE, W.A. Role of the capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus Type 1. PROC NATL ACAD SCI USA 86:5781-5789 (1989).
  4. TOMASZEK, T.A.; MAGAARD, V.W.; BRYAN, H.G.; MOORE, M.L.; MEEK, T.D. Chromophoric peptide substrates for the spectrophotometric assay of hiv-1 protease. BIOCHEM BIOPHYS RES COMMUN 168:274-280 (1990).
  5. HYLAND, L.J.; DAYTON, B.D.; MOORE, M.L.; SHU, A.Y.; HEYS, J.R.; MEEK, T.D. A radiometric assay for hiv-1 protease. ANAL BIOCHEM 188:408 (1990).
  6. PHYLIP, L.H.; RICHARDS, A.D.; KAY, J.; ET AL. Hydrolysis of synthetic chromogenic substrates by hiv-1 and hiv-2 proteinases. BIOCHEM BIOPHYS RES COMMUN 171:439 (1990).
  7. TAMBURINI, P.P.; DREYER, R.N.; HANSEN, J.; ET AL. A fluorometric assay for hiv-protease activity using high-performance liquid chromatography. ANAL BIOCHEM 186:363 (1990).
  8. RICHARDS, A.D.; PHYLIP, L.H.; FARMERI, W.G.; ET AL. Sensitive, soluble chromogenic substrates for hiv-1 proteinase. J BIOL CHEM 265:7733-7736 (1990).
  9. MATAYOSHI, E.D.; WANG, G.T.; KRAFFT, G.A.; ERICKSON, J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. SCIENCE 247:99-958 (1990).
  10. BILLICH, A.; WINKLER, G. Colorimetric assay of hiv-1 proteinase suitable for high-capacity screening. PEPTIDE RES 3:274 (1990).
  11. ROBERTS, N.A.; MARTIN, J.A.; KINCHINGTON, D.; ET AL. Rational design of peptide-based hiv proteinase inhibitors. SCIENCE 248:358-361 (1990).
  12. MEEK, T.D.; LAMBERT, D.M.; DREYER, G.B.; ET AL. Inhibition of hiv-1 protease in infected t-lymphocytes by synthetic peptide analogues. NATURE (LONDON) 343:90-92 (1990).
  13. RICH, D.H.; GREEN, J.; TOTH, M.V.; MARSHALL, G.R.; KENT, S.B. Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of hiv protease. J MED CHEM 33:1285-1288 (1990).
  14. MCQUADE, T.J.; TOMASSELLI, A.G.; LIU, L.; ET AL. A synthetic hiv-1 protease inhibitor with antiviral activity arrests hiv-like particle maturation. SCIENCE 247:454-456 (1990).
  15. ASHORN, P.; MCQUADE, T.J.; THAISRIVONGS, S.; TOMASSELLI, A.G.; TARPLEY, W.G.; MOSS B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. PROC NATL ACAD SCI USA 87:7472-7476 (1990).
  16. DREYER, G.B.; METCALF, B.W.; TOMASZEK, T.A.; ET AL. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. PROC NATL ACAD SCI USA 86:9752-9755 (1989).
  17. KEMPF, D.J.; NORBECK, D.W.; CODACOVI, L.; ET AL. Structure-based, c2 symmetric inhibitors of hiv protease. J MED CHEM 33:2687-2689 (1990).
  18. ERICKSON, J.; NEIDHART, D.J.; VANDRIE, J.; ET AL. DESIGN, ACTIVITY AND 2.8 A crystal structure of a c2 symmetric inhibitor complexed to hiv-1 protease. SCIENCE 249:527-533 (1990).
  19. BRYANT, M.L.; HEUCKEROTH, R.O..; KIMATA, J.T.; RATNER, L.; AND GORDON, J.I. Replication of human immunodeficiency virus 1 and moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid. PROC NATL ACAD SCI USA, 86:8655-8659 (1989).

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary